We found that GnRH agonist Triptorelin, which is in clinical use for ovarian function suppression of premenopausal breast cancer with high clinical risk of recurrence28, and was demonstrated to reduce breast cancer invasion37, reduced CTGF expression in mesenchymal transformed breast cancer in a dose-dependent manner. Here, GNRH1 is linked to breast carcinoma.